Cargando…

Advancing clinical development pathways for new CFTR modulators in cystic fibrosis

Cystic fibrosis (CF) is a life-shortening genetic disease affecting approximately 70 000 individuals worldwide. Until recently, drug development efforts have emphasised therapies treating downstream signs and symptoms resulting from the underlying CF biological defect: reduced function of the CF tra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mayer-Hamblett, Nicole, Boyle, Michael, VanDevanter, Donald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853537/ https://www.ncbi.nlm.nih.gov/pubmed/26903594 http://dx.doi.org/10.1136/thoraxjnl-2015-208123

Ejemplares similares

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
por: Nichols, Dave P., et al.
Publicado: (2019)

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials
por: VanDevanter, Donald R., et al.
Publicado: (2021)

Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review
por: VanDevanter, Donald R, et al.
Publicado: (2011)

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations
por: VanDevanter, Donald R, et al.
Publicado: (2010)

CFTR Modulators to the Rescue of Individuals with Cystic Fibrosis and Advanced Lung Disease
por: Myerburg, Mike, et al.
Publicado: (2021)

CFTR modulators: transformative therapies for cystic fibrosis
por: Dwight, Mary, et al.
Publicado: (2021)

Lived experiences of individuals with cystic fibrosis on CFTR-modulators
por: Page, Annelise, et al.
Publicado: (2022)

The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis
por: Harvey, Caitlyn, et al.
Publicado: (2022)

Nutritional impact of CFTR modulators in children with cystic fibrosis
por: Gaschignard, Margaux, et al.
Publicado: (2023)

Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis
por: Carmody, Lisa A., et al.
Publicado: (2018)

The effect of CFTR modulators on structural lung disease in cystic fibrosis
por: Mok, L. Clara, et al.
Publicado: (2023)

State of progress in treating cystic fibrosis respiratory disease
por: Flume, Patrick A, et al.
Publicado: (2012)

Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis
por: Muilwijk, Danya, et al.
Publicado: (2022)

A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis
por: Paynter, Alex, et al.
Publicado: (2022)

CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis
por: Lopes-Pacheco, Miquéias
Publicado: (2016)

Triplet CFTR modulators: future prospects for treatment of cystic fibrosis
por: Chaudary, Nauman
Publicado: (2018)

Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis
por: Levitte, Steven, et al.
Publicado: (2023)

Cystic Fibrosis, CFTR, and Colorectal Cancer
por: Scott, Patricia, et al.
Publicado: (2020)

A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
por: Habib, Al-Rahim R., et al.
Publicado: (2019)

CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis
por: Taylor-Cousar, Jennifer L.
Publicado: (2020)

Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis
por: Jarosz-Griffiths, Heledd H, et al.
Publicado: (2020)

CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
por: Lopes-Pacheco, Miquéias
Publicado: (2020)

CFTR modulator therapies – Effect on life expectancy in people with cystic fibrosis
por: Balfour-Lynn, I.M., et al.
Publicado: (2022)

Changes in the Cystic Fibrosis Airway Microbiome in Response to CFTR Modulator Therapy
por: Yi, Buqing, et al.
Publicado: (2021)

CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis
por: Benden, Christian, et al.
Publicado: (2021)

Validation of nasospheroids to assay CFTR functionality and modulator responses in cystic fibrosis
por: Calucho, Maite, et al.
Publicado: (2021)

Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators
por: Fajac, Isabelle, et al.
Publicado: (2021)

CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis
por: Saluzzo, Francesca, et al.
Publicado: (2022)

CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France
por: Regard, Lucile, et al.
Publicado: (2022)

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function
por: Zhang, Shuzhong, et al.
Publicado: (2018)

ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
por: Mall, Marcus A.
Publicado: (2020)

Eradication of early MRSA infection in cystic fibrosis: a novel study design for the STAR-ter trial
por: Cunningham, Fiona, et al.
Publicado: (2022)

CFTR and Ca(2+) Signaling in Cystic Fibrosis
por: Antigny, Fabrice, et al.
Publicado: (2011)

Strategies to circumvent the CFTR defect in cystic fibrosis
por: Becq, Frédéric, et al.
Publicado: (2013)

Not All Is CFTR – Neutrophils and Cholesterol in Cystic Fibrosis
por: Castellani, Stefano, et al.
Publicado: (2017)

Cystic Fibrosis and Oxidative Stress: The Role of CFTR
por: Moliteo, Evelina, et al.
Publicado: (2022)

Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time
por: Crull, Mathew R., et al.
Publicado: (2016)

CFTR-F508 pigs provide new clues to cystic fibrosis
Publicado: (2011)

Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy
por: Tewkesbury, Daniel H., et al.
Publicado: (2021)

The Exocrine Pancreas in Cystic Fibrosis in the Era of CFTR Modulation: A Mini Review
por: McKay, Isabelle R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ufhnr5p0i8adv014icm1mt273b